SGP8

SGP8 (IAVPGEVA) is an octapeptide produced by hydrolysis of soybean 11S globulin, which has the effects of regulating lipid metabolism, inflammation and fibrosis. SGP8 (IAVPGEVA) exhibits inhibitory activity against DPP4 and inhibits the JNK-c-Jun signaling pathway, and has the ability to inhibit non-alcoholic steatohepatitis (NASH) [1].

Product Specifications

CAS Number

[855790-98-6]

UNSPSC

12352209

Target

Dipeptidyl Peptidase

Type

Peptides

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/sgp8.html

Solubility

10 mM in DMSO

Smiles

N[C@]([C@@H](C)CC)([H])C(N[C@@H](C)C(N[C@@H](C(C)C)C(N1CCC[C@H]1C(NCC(N[C@H](C(N[C@@H](C(C)C)C(N[C@@H](C)C(O)=O)=O)=O)CCC(O)=O)=O)=O)=O)=O)=O

Molecular Formula

C34H58N8O11

Molecular Weight

754.87

References & Citations

[1]Peng Ma, et al. IAVPGEVA: Orally Available DPP4-Targeting Soy Glycinin Derived Octapeptide with Therapeutic Potential in Nonalcoholic Steatohepatitis.Journal of Agricultural and Food Chemistry. 2024, 72, 13, 7167–7178.